Prostate Cancer Diagnosis and Therapy Market Research Report - Forecast till 2030

Prostate Cancer Diagnosis and Therapy Market Size, Growth and Insights by Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and others), Component (Therapy and Diagnosis), End User (Specialty Centers, Hospitals & Clinics and others) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/1051-CR | January 2020 | Region: Global | 78 Pages         

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 18

2.2 RESEARCH OBJECTIVE 18

2.3 MARKET STRUCTURE 18

2.4 ASSUMPTIONS & LIMITATIONS 19

3 RESEARCH METHODOLOGY

3.1 DATA MINING 20

3.2 SECONDARY RESEARCH 21

3.3 PRIMARY RESEARCH 22

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23

3.5 FORECASTING TECHNIQUES 24

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25

3.6.1 BOTTOM-UP APPROACH 26

3.6.2 TOP-DOWN APPROACH 26

3.7 DATA TRIANGULATION 27

3.8 VALIDATION 27

4 MARKET DYNAMICS

4.1 OVERVIEW 28

4.2 DRIVERS 29

4.2.1 RISE IN INCIDENCE & PREVALENCE RATE OF PROSTATE CANCER 29

4.2.2 INCREASING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 29

4.2.3 REIMBURSEMENTS AND GROWING HEALTH INSURANCE 29

4.2.4 DRIVERS IMPACT ANALYSIS 30

4.3 RESTRAINTS 30

4.3.1 HIGH COST OF TREATMENT 30

4.3.2 SIDE-EFFECTS OF TREATMENT 30

4.3.3 RESTRAINTS IMPACT ANALYSIS 31

4.4 OPPORTUNITIES 31

4.4.1 LAUNCH OF INNOVATIVE TREATMENT PRODUCTS 31

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 32

5.1.1 THREAT OF NEW ENTRANTS 32

5.1.2 BARGAINING POWER OF SUPPLIERS 33

5.1.3 THREAT OF SUBSTITUTES 33

5.1.4 BARGAINING POWER OF BUYERS 33

5.1.5 INTENSITY OF RIVALRY 33

5.2 VALUE CHAIN ANALYSIS 34

5.2.1 R&D AND DESIGNING 35

5.2.2 MANUFACTURING 35

5.2.3 DISTRIBUTION 35

5.2.4 MARKETING & SALES 35

5.2.5 POST-SALES MONITORING 35

6 PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

6.1 INTRODUCTION 36

6.2 PROSTATIC ADENOCARCINOMA 37

6.3 SMALL CELL CARCINOMA 37

6.4 OTHERS 38

7 PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

7.1 INTRODUCTION 39

7.2 THERAPY 40

7.2.1 HORMONAL THERAPY 41

7.2.1.1 ANTI-ANDROGENS 42

7.2.1.2 LHRH ANALOGS 42

7.2.1.3 LHRH ANTAGONISTS 42

7.2.2 CHEMOTHERAPY 43

7.2.2.1 DOCETAXEL 44

7.2.2.2 CABAZITAXEL 44

7.2.2.3 OTHERS 44

7.2.3 RADIOTHERAPY DRUGS 45

7.2.4 IMMUNOTHERAPY 45

7.3 DIAGNOSIS 46

7.3.1 DIAGNOSTIC IMAGING 47

7.3.2 TISSUE BIOPSY 48

7.3.3 OTHERS 48

8 PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

8.1 INTRODUCTION 49

8.2 SPECIALITY CENTERS 50

8.3 HOSPITALS & CLINICS 50

8.4 OTHERS 51

9 Global Prostate Cancer Diagnosis and Therapy Market, by Region

9.1 INTRODUCTION 52

9.2 AMERICAS 54

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.2.1 NORTH AMERICA 58

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.2.1.1 US 61

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.2.1.2 CANADA 63

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.2.2 LATIN AMERICA 66

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3 EUROPE 69

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1 WESTERN EUROPE 72

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.1 GERMANY 75

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.2 FRANCE 78

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.3 UK 80

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.4 ITALY 82

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.5 SPAIN 85

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.1.6 REST OF WESTERN EUROPE 87

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.3.2 EASTERN EUROPE 90

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4 ASIA-PACIFIC 93

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.1 CHINA 97

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.2 JAPAN 99

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.3 AUSTRALIA 102

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.4 INDIA 104

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.5 SOUTH KOREA 106

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.4.6 REST OF ASIA-PACIFIC 109

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 112

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.5.1 MIDDLE EAST 115

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

9.5.2 AFRICA 117

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT

PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER

10 COMPETITIVE LANDSCAPE: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET

10.1 OVERVIEW 120

10.2 COMPETITIVE ANALYSIS 120

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 121

10.4 MARKET SHARE ANALYSIS 121

10.5 COMPETITIVE BENCHMARKING 122

10.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 123

10.7 KEY DEVELOPMENTS AND GROWTH STRATEGIES 123

10.7.1 COLLABORATION & PARTNERSHIP 124

10.7.2 AGREEMENT 124

10.7.3 PRODUCT APPROVAL AND LAUNCH 125

10.7.4 EXPANSION 126

10.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 126

10.8.1 SALES & OPERATING INCOME 126

10.8.2 R&D EXPENDITURE 127

11 COMPANY PROFILES

11.1 ABBVIE INC. 128

11.1.1 COMPANY OVERVIEW 128

11.1.2 FINANCIAL OVERVIEW 128

11.1.3 PRODUCTS/SERVICES OFFERED 129

11.1.4 KEY DEVELOPMENTS 129

11.1.5 SWOT ANALYSIS 129

11.1.6 KEY STRATEGIES 130

11.2 ASTRAZENECA 131

11.2.1 COMPANY OVERVIEW 131

11.2.2 FINANCIAL OVERVIEW 131

11.2.3 PRODUCTS/SERVICES OFFERED 132

11.2.4 KEY DEVELOPMENTS 132

11.2.5 SWOT ANALYSIS 132

11.2.6 KEY STRATEGIES 133

11.3 BAYER AG 134

11.3.1 COMPANY OVERVIEW 134

11.3.2 FINANCIAL OVERVIEW 134

11.3.3 PRODUCTS/SERVICES OFFERED 135

11.3.4 KEY DEVELOPMENTS 135

11.3.5 SWOT ANALYSIS 135

11.3.6 KEY STRATEGIES 136

11.4 SANOFI 137

11.4.1 COMPANY OVERVIEW 137

11.4.2 FINANCIAL OVERVIEW 137

11.4.3 PRODUCTS/SERVICES OFFERED 138

11.4.4 KEY DEVELOPMENTS 138

11.4.5 SWOT ANALYSIS 138

11.4.6 KEY STRATEGIES 138

11.5 IPSEN PHARMA 139

11.5.1 COMPANY OVERVIEW 139

11.5.2 FINANCIAL OVERVIEW 139

11.5.3 PRODUCTS/SERVICES OFFERED 140

11.5.4 KEY DEVELOPMENTS 140

11.5.5 SWOT ANALYSIS 141

11.5.6 KEY STRATEGIES 141

11.6 ASTELLAS PHARMA INC. 142

11.6.1 COMPANY OVERVIEW 142

11.6.2 FINANCIAL OVERVIEW 142

11.6.3 PRODUCTS OFFERED 143

11.6.4 KEY DEVELOPMENTS 143

11.6.5 SWOT ANALYSIS 144

11.6.6 KEY STRATEGIES 144

11.7 JOHNSON & JOHNSON SERVICES INC. 145

11.7.1 COMPANY OVERVIEW 145

11.7.2 FINANCIAL OVERVIEW 145

11.7.3 PRODUCTS OFFERED 146

11.7.4 KEY DEVELOPMENTS 146

11.7.5 SWOT ANALYSIS 147

11.7.6 KEY STRATEGIES 147

11.8 TOLMAR PHARMACEUTICALS, INC. 148

11.8.1 COMPANY OVERVIEW 148

11.8.2 FINANCIAL OVERVIEW 148

11.8.3 PRODUCTS OFFERED 148

11.8.4 KEY DEVELOPMENTS 148

11.8.5 SWOT ANALYSIS 149

11.8.6 KEY STRATEGIES 149

11.9 DENDREON PHARMACEUTICALS LLC 150

11.9.1 COMPANY OVERVIEW 150

11.9.2 FINANCIAL OVERVIEW 150

11.9.3 PRODUCTS OFFERED 150

11.9.4 KEY DEVELOPMENTS 150

11.9.5 SWOT ANALYSIS 151

11.9.6 KEY STRATEGIES 151

11.10 FERRING BV 152

11.10.1 COMPANY OVERVIEW 152

11.10.2 FINANCIAL OVERVIEW 152

11.10.3 PRODUCTS OFFERED 152

11.10.4 KEY DEVELOPMENTS 152

11.10.5 SWOT ANALYSIS 153

11.10.6 KEY STRATEGIES 153

12 APPENDIX

12.1 REFERENCES 154

12.2 RELATED REPORTS 154

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 19

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

TABLE 3 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 36

TABLE 4 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR PROSTATIC ADENOCARCINOMA, BY REGION

2020-2027 (USD MILLION) 37

TABLE 5 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR SMALL CELL CARCINOMA, BY REGION

2020-2027 (USD MILLION) 37

TABLE 6 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHERS, BY REGION 2020-2027 (USD MILLION) 38

TABLE 7 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT 2020-2027 (USD MILLION) 39

TABLE 8 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR THERAPY, BY TYPE 2020-2027 (USD MILLION) 40

TABLE 9 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR THERAPY, BY REGION 2020-2027 (USD MILLION) 40

TABLE 10 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 41

TABLE 11 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY REGION 2020-2027

(USD MILLION) 41

TABLE 12 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR ANTI-ANDROGENS, BY REGION 2020-2027 (USD MILLION) 42

TABLE 13 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR LHRH ANALOGS, BY REGION 2020-2027 (USD MILLION) 42

TABLE 14 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR LHRH ANTAGONISTS, BY REGION 2020-2027

(USD MILLION) 42

TABLE 15 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 43

TABLE 16 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY REGION 2020-2027 (USD MILLION) 43

TABLE 17 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR DOCETAXEL, BY REGION 2020-2027 (USD MILLION) 44

TABLE 18 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CABAZITAXEL, BY REGION 2020-2027 (USD MILLION) 44

TABLE 19 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHER CHEMOTHERAPY, BY REGION 2020-2027

(USD MILLION) 44

TABLE 20 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR RADIOTHERAPY DRUGS, BY REGION 2020-2027

(USD MILLION) 45

TABLE 21 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR IMMUNOTHERAPY, BY REGION 2020-2027 (USD MILLION) 45

TABLE 22 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR DIAGNOSIS, BY TYPE 2020-2027 (USD MILLION) 46

TABLE 23 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR DIAGNOSIS, BY REGION 2020-2027 (USD MILLION) 46

TABLE 24 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR DIAGNOSTIC IMAGING, BY REGION 2020-2027

(USD MILLION) 47

TABLE 25 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR TISSUE BIOPSY, BY REGION 2020-2027 (USD MILLION) 48

TABLE 26 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHER DIAGNOSIS, BY REGION 2020-2027 (USD MILLION) 48

TABLE 27 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 28 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR SPECIALITY CENTERS, BY REGION 2020-2027

(USD MILLION) 50

TABLE 29 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HOSPITALS & CLINICS, BY REGION 2020-2027

(USD MILLION) 50

TABLE 30 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHER END USERS, BY REGION 2020-2027 (USD MILLION) 51

TABLE 31 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION 2020–2027 (USD MILLION) 53

TABLE 32 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 55

TABLE 33 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 34 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 55

TABLE 35 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 56

TABLE 36 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 56

TABLE 37 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 56

TABLE 38 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 57

TABLE 39 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 40 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 58

TABLE 41 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 42 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 59

TABLE 43 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 59

TABLE 44 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 59

TABLE 45 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027

(USD MILLION) 60

TABLE 46 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 60

TABLE 47 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 48 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 49 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 61

TABLE 50 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 61

TABLE 51 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 62

TABLE 52 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 62

TABLE 53 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 62

TABLE 54 US: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 55 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 56 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 63

TABLE 57 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 64

TABLE 58 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 64

TABLE 59 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 60 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 65

TABLE 61 CANADA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 62 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 63 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 66

TABLE 64 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 66

TABLE 65 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 67

TABLE 66 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027

(USD MILLION) 67

TABLE 67 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 67

TABLE 68 LATIN AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 69 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 69

TABLE 70 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 71 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 70

TABLE 72 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 70

TABLE 73 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 71

TABLE 74 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 71

TABLE 75 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 71

TABLE 76 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 77 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 78 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 79 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 73

TABLE 80 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 74

TABLE 81 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 74

TABLE 82 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 74

TABLE 83 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 75

TABLE 84 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 85 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 86 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 76

TABLE 87 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 76

TABLE 88 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 76

TABLE 89 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 77

TABLE 90 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 77

TABLE 91 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 77

TABLE 92 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 93 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 78

TABLE 94 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 78

TABLE 95 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 79

TABLE 96 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 79

TABLE 97 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 79

TABLE 98 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 99 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 100 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 80

TABLE 101 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 81

TABLE 102 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 81

TABLE 103 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 81

TABLE 104 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 82

TABLE 105 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 106 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 107 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 83

TABLE 108 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 83

TABLE 109 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 83

TABLE 110 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 84

TABLE 111 ITALY MERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 84

TABLE 112 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 84

TABLE 113 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 114 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 85

TABLE 115 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 85

TABLE 116 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 86

TABLE 117 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 86

TABLE 118 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86

TABLE 119 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 87

TABLE 120 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 121 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027

(USD MILLION) 87

TABLE 122 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 88

TABLE 123 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 88

TABLE 124 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE

2020-2027 (USD MILLION) 88

TABLE 125 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 89

TABLE 126 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 127 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 128 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 90

TABLE 129 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 90

TABLE 130 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 91

TABLE 131 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE

2020-2027 (USD MILLION) 91

TABLE 132 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 91

TABLE 133 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 92

TABLE 134 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94

TABLE 135 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 136 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 94

TABLE 137 ASIA-PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 95

TABLE 138 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 95

TABLE 139 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027

(USD MILLION) 95

TABLE 140 ASIA-PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 96

TABLE 141 ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 96

TABLE 142 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 143 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 97

TABLE 144 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 97

TABLE 145 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 98

TABLE 146 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 98

TABLE 147 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 98

TABLE 148 CHINA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 149 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 150 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 99

TABLE 151 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 100

TABLE 152 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 100

TABLE 153 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 100

TABLE 154 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 101

TABLE 155 JAPAN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 101

TABLE 156 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 157 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 102

TABLE 158 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 102

TABLE 159 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 103

TABLE 160 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 103

TABLE 161 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103

TABLE 162 AUSTRALIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 104

TABLE 163 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 164 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 104

TABLE 165 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 105

TABLE 166 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027 (USD MILLION) 105

TABLE 167 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 105

TABLE 168 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 106

TABLE 169 INDIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 170 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 171 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 107

TABLE 172 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 107

TABLE 173 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 107

TABLE 174 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027

(USD MILLION) 108

TABLE 175 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 108

TABLE 176 SOUTH KOREA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 108

TABLE 177 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 178 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 109

TABLE 179 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 109

TABLE 180 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 110

TABLE 181 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE

2020-2027 (USD MILLION) 110

TABLE 182 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 110

TABLE 183 REST OF ASIA PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 111

TABLE 184 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 112

TABLE 185 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 186 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 113

TABLE 187 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 113

TABLE 188 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 114

TABLE 189 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE

2020-2027 (USD MILLION) 114

TABLE 190 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 114

TABLE 191 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 115

TABLE 192 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 193 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 115

TABLE 194 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 116

TABLE 195 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE

2020-2027 (USD MILLION) 116

TABLE 196 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027

(USD MILLION) 116

TABLE 197 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 117

TABLE 198 MIDDLE EAST: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 117

TABLE 199 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 200 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 118

TABLE 201 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY THERAPY, 2020–2027 (USD MILLION) 118

TABLE 202 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HORMONAL THERAPY, BY TYPE 2020-2027

(USD MILLION) 118

TABLE 203 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR CHEMOTHERAPY, BY TYPE 2020-2027 (USD MILLION) 119

TABLE 204 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 119

TABLE 205 AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 119

TABLE 206 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 123

TABLE 207 COLLABORATION & PARTNERSHIP: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 124

TABLE 208 AGREEMENT: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 124

TABLE 209 PRODUCT APPROVAL AND LAUNCH: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 125

TABLE 210 EXPANSION: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 126

TABLE 211 MAJOR PLAYERS R&D EXPENDITURE, 2020 (USD MILLION) 127

TABLE 212 ABBVIE INC.: PRODUCTS/SERVICES OFFERED 129

TABLE 213 ABBVIE INC.: KEY DEVELOPMENTS 129

TABLE 214 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 132

TABLE 215 ASTRAZENECA: KEY DEVELOPMENTS 132

TABLE 216 BAYER AG: PRODUCTS/SERVICES OFFERED 135

TABLE 217 BAYER AG: KEY DEVELOPMENTS 135

TABLE 218 SANOFI: PRODUCTS/SERVICES OFFERED 138

TABLE 219 IPSEN PHARMA: PRODUCTS/SERVICES OFFERED 140

TABLE 220 IPSEN PHARMA: KEY DEVELOPMENTS 140

TABLE 221 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 143

TABLE 222 ASTELLAS PHARMA INC.: KEY DEVELOPMENTS 143

TABLE 223 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED 146

TABLE 224 JOHNSON & JOHNSON SERVICES INC.: KEY DEVELOPMENTS 146

TABLE 225 TOLMAR PHARMACEUTICALS, INC.: PRODUCTS OFFERED 148

TABLE 226 TOLMAR PHARMACEUTICALS, INC.: KEY DEVELOPMENTS 148

TABLE 227 DENDREON PHARMACEUTICALS LLC: PRODUCTS OFFERED 150

TABLE 228 FERRING BV: PRODUCTS OFFERED 152

14 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 17

FIGURE 2 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET: STRUCTURE 18

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 25

FIGURE 1 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 28

FIGURE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 32

FIGURE 3 VALUE CHAIN ANALYSIS OF THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 34

FIGURE 4 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE 2020 & 2027 (USD MILLION) 36

FIGURE 5 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT 2020 & 2027 (USD MILLION) 39

FIGURE 6 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER 2020 & 20276 (USD MILLION) 49

FIGURE 7 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION 2020 & 2027 (USD MILLION) 52

FIGURE 8 AMERICAS: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION, 2020 (%) 54

FIGURE 9 NORTH AMERICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 58

FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION 2020 (%) 69

FIGURE 11 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY COUNTRY 2020 (%) 72

FIGURE 12 ASIA-PACIFIC: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 93

FIGURE 13 MIDDLE EAST & AFRICA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION, 2020 (%) 112

FIGURE 14 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 121

FIGURE 15 GLOBAL PROSTATE CANCER THERAPY MARKET, COMPANY SHARE ANALYSIS (% SHARE) 121

FIGURE 16 BENCHMARKING OF MAJOR COMPETITORS IN THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET 122

FIGURE 17 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, COMPETITIVE LANDSCAPE (% SHARE) 123

FIGURE 18 SALES & OPERATING INCOME, 2020 (USD BILLION) 126

FIGURE 19 ABBVIE INC.: FINANCIAL OVERVIEW 128

FIGURE 20 ABBVIE INC.: SWOT ANALYSIS 129

FIGURE 21 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 131

FIGURE 22 ASTRAZENECA: SWOT ANALYSIS 132

FIGURE 23 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 134

FIGURE 24 BAYER AG: SWOT ANALYSIS 135

FIGURE 25 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 137

FIGURE 26 SANOFI: SWOT ANALYSIS 138

FIGURE 27 IPSEN PHARMA: FINANCIAL OVERVIEW SNAPSHOT 139

FIGURE 28 IPSEN PHARMA: SWOT ANALYSIS 141

FIGURE 29 ASTELLAS PHARMA INC: FINANCIAL OVERVIEW SNAPSHOT 142

FIGURE 30 ASTELLAS PHARMA INC.: SWOT ANALYSIS 144

FIGURE 31 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT 145

FIGURE 32 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS 147

FIGURE 33 TOLMAR PHARMACEUTICALS, INC.: SWOT ANALYSIS 149

FIGURE 34 DENDREON PHARMACEUTICALS LLC: SWOT ANALYSIS 151

FIGURE 35 FERRING BV: SWOT ANALYSIS 153

Prostate Cancer Diagnosis and Therapy Market

The Prostate Cancer Diagnosis and Therapy Market is Projected to reach USD 10.1 billion at a 7.50% CAGR during the ongoing forecast period of 2022-2030.

Segmentation

By Type Prostatic Adenocarcinoma Small Cell Carcinoma
By Component Therapy And Diagnosis
By End User Specialty Centers Hospitals & Clinics

Key Players

  • Abbvie Inc. (US)
  • AstraZeneca (UK)
  • Bayer AG (Germany)
  • Sanofi (France)
  • IpsenPharma (France)
  • AstellasPharma Inc. (Japan)
  • Johnson & Johnson Services Inc. (US)
  • Tolmar Pharmaceuticals Inc.(US)

Drivers

  • Diet that’s full of high-fat foods and junk food
  • A sedentary lifestyle
  • Hereditary genes
  • Smoking and heavy alcohol usage.
Speak to Analyst Request a Free Sample

Prostate Cancer Diagnosis and Therapy Market Overview


A modest but steady 7.50% CAGR is being experienced by the prostate cancer diagnosis and therapy market. By the end of 2030, prostate cancer diagnosis and therapy market value is anticipated to reach USD 10.1 billion. Older men (those older than 55) are more likely to develop prostate cancer.


More than 80% of the world's elderly men suffer from prostate cancer in some form.


COVID 19 Analysis


In March of 2020, COVID-19 was first introduced to the global scene. In the beginning, governments responded early because this disease was dangerous and killed a very small share of those that contracted it (less than 1%).


Worldwide, governments have imposed indefinite quarantines and lockdowns in response. This is adversely affecting the prostate cancer diagnosis and therapy market. Patients have been less likely to seek treatment immediately as a result.


Prostate Cancer Diagnosis and Therapy Market Dynamics:


Drivers


In recent years there has been tremendous growth in prostate cancer diagnostics due to many factors. Health insurance coverage overseas is rapidly expanding. Governments and organizations are also spending more and more on prostate cancer research. A second factor driving the growth of prostate cancer is the fact that insurance companies pay doctors to treat and conduct research in the area.


Besides a diet high in fat and junk food, sedentary lifestyles, genetic makeup, and the use of heavy alcohol and smoking are also contributing to growth.


Restraints


Prostate cancer treatment requires chemotherapy like any other major cancer. The process can take a while. As a result, the treatments may have dangerous side effects. A deadly stroke has been linked to the chemotherapy process, for example. High treatment costs for prostate cancer are another major deterrent. Most people currently cannot afford treatment for it.


Technology Analysis


The prostate cancer diagnosis and therapy market has been heavily invested in and is reaping a big profit in the form of new products and therapeutics that are more effective (and costlier) than their predecessors. Diagnosing prostate cancer is a prime example.


A new screening method is the color doppler ultrasound. With this technique, cancer is detected at an early stage and doctors can treat patients in time. Prostate flow is measured. Normally, normal tissues and glands see much less blood flowing through them than tumors do.


Segment Overview


Based on Type:


Adenocarcinomas of the prostate and small cell carcinomas are further segmented.


Based on Product:


Analyzers, reagents, and consumers are further divided into segments.


Based on Component:


A global analysis of prostate cancer diagnosis and therapy market segment further breaks it down into the therapy market and prostate cancer diagnosis market.


Based on Therapy:




  • Therapy and diagnosis are further broken down into chemotherapy, radiotherapy drugs, immunotherapy, and hormonal therapy.




    • There are three basic types of hormonal therapy: antiandrogens, LHLR analogs, and LHLR antagonists.




    • A primary difference between chemotherapy and other therapies is the use of docetaxel and cabazitaxel




    • Further subcategories of diagnosis include diagnostic imaging, tissue biopsy, and other components.






Based on End-User:


A specialty center, hospital, and clinic are the components included in the end-user segment.


Regional Analysis


Based on the type of cancer diagnosed and the treatment chosen, the marketplace is divided into four sectors including the European Union, the Asia-Pacific Regions, The Americas, and The Middle East and North Africa (MENA) region. 


Prostate cancer diagnosis and treatment are the largest business in the American market. This has been confirmed by current statistics of the year 2018. As predicted, Prostate Cancer Diagnosis and Therapy Market size and share will continue to grow. American and Canadian populations are rapidly aging, which has led to this trend. This is leading to an increase in prostate cancer cases in those countries. 


Also, the number of men receiving treatment for prostate cancer is increasing, often during the early stage, when it is still treatable. There is increasingly more education being provided to American men concerning early diagnosis, screening, and treatment. This is increasing deaths from prostate cancer. 


In 2019, there were 174,650 new prostate cancer cases reported to the American Cancer Society. 31,620 men in America die every year from this disease. 


In terms of the size of the Prostate Cancer Diagnosis and Therapy Market, the European Union holds the second largest share. Considering screening, diagnosis, and treatment of prostate cancer for the entire European Union, there are two main regions: Eastern Europe, and Western Europe. Germany, the UK, French, Spanish, Italians, and the rest of the Western European nations have the most prostate cancer cases. 


Over the next few decades, the population of the entire European Union will age rapidly. The combination of increased awareness of prostate cancer is causing a significant increase in screenings. The result is more prostate cancer diagnoses and prostate cancer cases reported. 


All global regions except the Asia-Pacific have the highest rate of growth. This is largely due to the growing economies of India and China. Health insurance plans are multiplying in the United States and Canada due to this. 


Both these countries have growing middle classes, increasing disposable income, and discretionary purchasing power. Prostate cancer cases are increasing rapidly as a result of this increase in diagnosis and treatment. The adoption of Western lifestyles and diets is increasing in India and China. Obesity has been traditionally linked to prostate cancer, especially among older men.


Competitive Landscape


Although there are significant barriers to entry, a prostate cancer diagnosis is highly competitive. The lower CAGR is one factor contributing to this. The saturation of the prostate cancer diagnosis and therapy market is also a contributing factor. Companies are spending significant amounts of money on research and development to remain competitive. This helps them develop new products and solutions for the prostate cancer diagnostic market, including diagnosis and screening. They are noteworthy for their effectiveness over the past few decades.


Through mergers and acquisitions and joint ventures, new and established players are trying to acquire market share and gain access to the prostate cancer diagnosis and therapy market.


Located in the United States, Abbvie Inc. researches prostate cancer. As a large company, the company can invest heavily in research and development. With its innovative products and technologies, it maintains a competitive advantage by introducing new products and technologies.


Combining small molecules with natural antibodies is a technique they're using to boost the body's immune system. They are therefore more effective in targeting thyroid cancer-related antigens. 


Recent Developments




  • A supplemental New Drug Application (sNDA) for Astra Pharma has been approved by the American Food and Drug Administration (FDA). Three different forms of prostate cancer could be cured with this oral medication.




  • A 15-year joint-venture was formed by IpsenPharma and Debiopharm. The researchers hope to use Decapeptyl to treat some prostate cancer types more effectively.




  • Through a joint venture with nonprofit Calibr (which has no commercial purpose), Abbvie and Calibr are trying to develop more effective ways of treating prostate cancers with solid tumors.




A rapidly aging global population, changing lifestyles, and an expansion of insurance coverage are all factors driving growth. This demand is being met through extensive investments in researching and developing new treatments, diagnostics, screening procedures, and therapies.


Report Overview


The prostate cancer diagnosis and therapy market search report involve detailed analysis and evaluation of the situation of cancer and prostate in the prostate cancer diagnosis and therapy market and the scope of treatment that is possible. It provides an outlook to the investors to help them make sound decisions on which market to invest in and how much as it provides a 360-degree analysis of the entire situation which covers the opportunities, strengths, challenges, and even restraints.This report covers the current and the expected growth rate and the market size and market share of the prostate cancer diagnosis and therapy market. It segments the report and provides a detailed segment overview to have an appropriate analysis of the type of users, components, markets, regions, etc.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 10.1 Billion
  CAGR   7.50%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Component, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbvie Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), IpsenPharma (France), AstellasPharma Inc. (Japan), Johnson & Johnson Services Inc. (US), Tolmar Pharmaceuticals, Inc.(US), Dendreon Pharmaceuticals LLC (US), Ferring BV (Switzerland)
  Key Market Opportunities   Leading pharma to launch products for treatment
  Key Market Drivers   Diet that’s full of high-fat foods and junk food, a sedentary lifestyle, hereditary genes, and smoking and heavy alcohol usage.


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The valuation of the prostate cancer diagnosis and therapy market is estimated to reach USD 10.1 BN by the end of 2030.

Prostate cancer diagnosis and therapy market is projected to grow at approximately 7.50% CAGR during the assessment period.

Increasing expenditure on oncology medicine research and favorable reimbursements process and health insurance are the major tailwinds pushing the growth of the global prostate cancer diagnosis and therapy market.

North America holds the largest share in the global prostate cancer diagnosis and therapy market, followed by Europe and the Asia Pacific, respectively.

Abbvie Inc. (US), Dendreon Pharmaceuticals LLC (US), AstraZeneca (UK), Sanofi (France), Bayer AG (Germany), Ipsen Pharma (France), Johnson & Johnson Services Inc. (US), Astellas Pharma Inc. (Japan), Ferring BV (Switzerland), and Tolmar Pharmaceuticals, Inc.(US), are some of the major players operating in the prostate cancer diagnosis and therapy market.